Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid.

The effect of poly-L-aspartic acid (PA) on the crystal structure of calcium oxalate crystals grown after spontaneous nucleation was evaluated as a function of relative supersaturation and calcium:oxalate ratio in a buffered salt solution, with pH and ionic strength in the range of normal human urine. PA was used as a model for naturally occurring acidic urine proteins that have been shown to inhibit nucleation and growth of calcium oxalate crystals. The crystals grown were characterized by optical microscopy and X-ray powder diffraction. It was observed that calcium oxalate monohydrate was the preferred crystalline form in the absence of added PA, and it was the only crystalline form obtained at most conditions tested without PA. However, the presence of PA favored the formation of calcium oxalate dihydrate crystals, when present in adequate quantities. The quantity of PA required to affect this change in preferred crystal structure was increased at higher supersaturations and at lower calcium:oxalate ratios, exhibiting a non-linear dependence on both variables. PA was also shown to be a kinetic inhibitor of calcium oxalate dihydrate crystallization. Aspartic acid monomer was found to cause no change in the preferred structure of calcium oxalate monohydrate at mass concentrations well beyond those required with PA to obtain 100% calcium oxalate dihydrate, indicating the critical importance of the polymeric nature of PA for this effect on crystal structure.

[1]  E. Worcester,et al.  Osteopontin Inhibits Nucleation of Calcium Oxalate Crystals a , 1995, Annals of the New York Academy of Sciences.

[2]  N. Mandel,et al.  Crystal-membrane interaction in kidney stone disease. , 1994, Journal of the American Society of Nephrology : JASN.

[3]  N. Garti,et al.  The Influence of Surfactants on the Crystallization of Calcium Oxalate Hydrates , 1994 .

[4]  P. C. Rieke,et al.  Ceramic Thin-Film Formation on Functionalized Interfaces Through Biomimetic Processing , 1994, Science.

[5]  W. Grzeszczak,et al.  [Pathogenesis and treatment of kidney stones]. , 1994, Wiadomosci lekarskie.

[6]  M. Jewett,et al.  Clinical and biochemical differences in patients with pure calcium oxalate monohydrate and calcium oxalate dihydrate kidney stones. , 1994, The Journal of urology.

[7]  D. Denhardt,et al.  Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  E. Worcester,et al.  The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  E. Neilson,et al.  Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Mandel,et al.  Crystal-cell interactions: crystal binding to rat renal papillary tip collecting duct cells in culture. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  R. Ryall,et al.  Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? , 1990, Clinica chimica acta; international journal of clinical chemistry.

[12]  G. Mandel,et al.  Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. , 1989, The Journal of urology.

[13]  G. Mandel,et al.  Urinary tract stone disease in the United States veteran population. I. Geographical frequency of occurrence. , 1989, The Journal of urology.

[14]  W. Butler,et al.  The nature and significance of osteopontin. , 1989, Connective tissue research.

[15]  J. Garancis,et al.  Calcium oxalate crystal interaction with rat renal inner papillary collecting tubule cells. , 1987, The Journal of urology.

[16]  S. Ljunghall,et al.  Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[17]  G. Mandel,et al.  Membrane interactions with calcium oxalate crystals: variation in hemolytic potentials with crystal morphology. , 1986, The Journal of urology.

[18]  L. Smith,et al.  EQUIL2: a BASIC computer program for the calculation of urinary saturation. , 1985, The Journal of urology.

[19]  S. Weiner,et al.  Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Smith,et al.  Calcium oxalate dihydrate formation in urine. , 1984, Kidney international.

[21]  J. S. Elliot,et al.  Calcium oxalate crystalluria: crystal size in urine. , 1980, The Journal of urology.

[22]  H. Fleisch Inhibitors and promoters of stone formation. , 1978, Kidney international.

[23]  H. Ito,et al.  Acidic peptide and polyribonucleotide crystal growth inhibitors in human urine. , 1977, The American journal of physiology.